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Introduction: Hepatic veno-occlusive disease (VOD, or
sinusoidal obstruction syndrome) is a potentially fatal
complication of stem cell transplantation (SCT). Severe VOD
(sVOD) is usually characterized by multi-organ failure (MOF)
and >80% mortality. Deﬁbrotide (DF) is approved in the EU
for the treatment of sVOD in SCT. We report the ﬁnal
results of a large, international compassionate use program
(CUP; 1998-2009) in Europe, the US, Asia, and the Middle
East.
Methods: DF was provided on a compassionate basis or via
single patient (pt) emergency-use requests post-SCT or
chemo-/radiotherapy. Eligibility, DF use, safety, and out-
comes were collected with case record forms. In the US, pts
met Baltimore criteria for VOD and had MOF. At other sites,
pts met Seattle or Baltimore, ultrasound, and/or histological
criteria. Initial dosing recommendation was 10 mg/kg/d (4
divided doses/d IV) titrated up to 60 mg/kg/d based on
tolerability/response. Following results of a US Phase 2 study,
the recommended dose was 25 mg/kg/d. Treatment duration
was up to investigators. Data included adverse events (AEs)
and survival at Day+100 post-SCT or start of chemo-/
radiotherapy.
Results: Safety/outcome data were submitted voluntarily for
710 pts receiving 1 DF dose. VOD developed post-SCT in
89% (71% allogeneic; 16% autologous; 2% missing), and post-
chemo-/radiotherapy in 11%. Median age was 25 (range, 0.2-
70) years; 43% were <18 years.
Median days to VOD onset was 13. Symptoms were bili-
rubin >2 mg/dL (88% of patients), weight gain >5% (82%),
hepatomegaly (77%), ascites (67%), right upper quadrant pain
(64%), and MOF (41%). Per Bearman criteria or MOF, 60% had
sVOD.
The median dose was 25 mg/kg/d given for a median of
15d.
AEs were reported in 378 pts (53%; <20% related);
most were serious (364) and fatal (350). Causes of death
were generally reported as AEs; hence the most common
new or worsening AEs were MOF (144, all fatal), VOD
(79, 78 fatal), and sepsis (49, 48 fatal). Serious AEs/fa-
talities were generally similar across doses. Hemorrhage
was reported by 85 pts (55 serious, including 37 fatal),
most commonly gastrointestinal (33) or respiratory (24).
Central nervous system (CNS) hemorrhage was reported
in 10 pts. Respiratory tract hemorrhage was highest in
the 60/80 mg/kg/d dose group (9%) vs lower doses (<5%),
but gastrointestinal and CNS hemorrhages were similar
across doses (6%). Withdrawals due to an AE (63) were
mostly due to hemorrhage (50), primarily gastrointestinal
(22).The Kaplan-Meier (KM) estimate of Day+100 sur-
vival was 54%. The ﬁgure shows KM survival curve by
dose group; in the 25 mg/kg/d group (the approved
EU dose) estimated survival was 58% at Day+100
(Figure 1).
Conclusions: DF was generally well tolerated in this large
CUP; AEs were typical for VOD pts. Consistent with prior
studies, survival was 54% at Day+100. Subgroup analyses
support 25 mg/kg/d as the optimal dose.
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Background: AdV is associated with signiﬁcant morbidity
and mortality. No drug is currently approved for AdV. BCV is
an orally available lipid-conjugate of cidofovir (CDV) that
has demonstrated promise as preemptive therapy in allo
HCT patients (pts) with asymptomatic AdV viremia (VL) in a
Phase 2 study. The pilot portion of a Phase 3 BCV study for
AdV (CMX001-304, AdVise Study; NCT02087306) was
initiated in MAR2014. Preliminary results for 26 subjects
enrolled through 15JUL2014 are described (data cut-off
12SEP2014).
Methods: All subjects receive open-label BCV 100 mg ( 50
kg) or 2 mg/kg (< 50 kg) twice a week.
Results: For the 26 subjects, median age ¼ 6.5 y (range:
0-29), 58% < 12 y; 20 allo HCT pts (16 with disseminated
disease), 4 solid organ transplant pts and 2 chemotherapy
pts; median VL in plasma by quantitative polymerase
chain reaction (PCR) at baseline (BL) 4.8 log10c/mL (range:
undetectable [< 2 log10; < LOD] to > 10 log10) (n ¼ 23);
46% were AdV positive in respiratory secretions, 58% in
Figure 1.
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prior IV CDV exposure. Median BCV treatment duration 54
days (range: 1 to 108). Suppression of plasma AdV VL to <
LOD by quantitative PCR was 61% (14/23) at any time on-
treatment and 52% (12/23) at last on-treatment value.
Median change in plasma AdV VL from BL to nadir was
-1.4 log10 c/mL (range: -8.0 to 0.6), with 65% (15/23)
achieving  3 log10 decrease to nadir (or to < LOD). In-
dividual plots of plasma AdV VL over time are shown in
the ﬁgure. In subjects with positive qualitative AdV PCR at
BL, 42% (5/12) cleared AdV in respiratory secretions, 33%
(5/15) in urine and 27% (4/15) in stool. Six of the 11
subjects with prior IV CDV achieved AdV VL < LOD and
one had > 2 log10 decline at last on-treatment value.
Treatment-related AEs requiring premature BCV dis-
continuation were limited to severe diarrhea (in two
subjects). Among the 48 subjects enrolled through
19SEP2014, there were 17 deaths, including two of seven
subjects with asymptomatic disease (29%), in 11 of 29 allo
HCT subjects with disseminated AdV (38%) and four of 12
subjects with non-allo HCT disseminated AdV (33%), rep-
resenting an overall mortality rate to-date of 35% (17/48),
with a median duration of observation of 57 days for
living pts. Safety and efﬁcacy data from newly enrolled
subjects will be included in the presentation.
Conclusions: These preliminary results from 26 subjects
enrolled in the pilot portion of AdVise show mortality
rates of < 40% across subjects with limited and dissemi-
nated AdV and across populations with varying identiﬁed
risk factors (HCT, SOT, other); these are lower mortality
rates than those in the literature for disseminated disease.
AdV viremia was suppressed to undetectable in over half
of enrolled subjects. No new safety concerns were iden-
tiﬁed in this complex patient population. These data
support progression to deﬁnitive Phase 3 BCV study for
AdV.
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Introduction: Severe hepatic veno-occlusive disease (VOD,
also called sinusoidal obstruction syndrome) with multi-
organ failure (MOF) is a life-threatening complication of
hematopoietic stem cell transplant (HSCT), with a mor-
tality rate of >80%. Deﬁbrotide has a protective effect on
injured endothelium and restores thrombo-ﬁbrinolytic
balance. In severe VOD, deﬁbrotide improves complete
response (CR) rates and survival at Day+100 post-HSCT,
with a favorable safety proﬁle. In the EU, deﬁbrotide is
approved for treatment of severe hepatic VOD in HSCT
therapy in adults and children. In the US, there are no
approved therapies for VOD; however, deﬁbrotide is
available through an expanded access, protocol-directed
treatment IND (T-IND). The T-IND gathers data on safety/
efﬁcacy of deﬁbrotide in patients (pts) with severe and
non-severe VOD post-HSCT, as well as post-chemotherapy
(CT) alone.
Methods: The original T-IND protocol required VOD diag-
nosed by Baltimore criteria (total bilirubin 2.0 mg/dL
with 2 of hepatomegaly, ascites, or 5% weight gain)
with MOF (renal and/or pulmonary failure) following HSCT;
the study was amended to include non-severe VOD (deﬁned
as no MOF) post-HSCT or post-CT. Exclusion criteria include
clinically signiﬁcant bleeding or need for >1 vasopressor.
Deﬁbrotide was given as a 2-hour infusion at 6.25 mg/kg IV
q6h (25 mg/kg/d) for a recommended 21 days.
Results: This interim safety analysis update is based on 612
pts enrolled from December 2007 to December 2013
(including 99 in 2013) who received 1 deﬁbrotide dose.
Median patient age was 12 years (range <0.1e69).
Overall, 1 treatment emergent adverse event (AE) was
reported in 454 pts (74.2%). Of these, 138 pts (22.5%) had AEs
possibly, probably, or deﬁnitely related to deﬁbrotide.
Related AEs in >2.0% included pulmonary hemorrhage
(4.7%), gastrointestinal hemorrhage (3.6%), epistaxis (3.1%),
and hypotension (2.8%). Serious AEs (SAEs) were reported by
368 pts (60.1%) and most were assessed as not related to
deﬁbrotide; 82 pts (13.4%) had an SAE at least possibly
related to study treatment, most commonly pulmonary
hemorrhage (3.9%) and gastrointestinal hemorrhage (2.9%).
AEs leading to death occurred in 254 pts (41.5%); these AEs
were deemed possibly related to study medication in only 17
pts (2.8%).
Previously reported efﬁcacy data at Day+100 in 425
evaluable pts showed survival of 55% (by Kaplan-Meier
